Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
The latest update is out from Genmab ( (GMAB) ).
On May 12, 2025, Genmab A/S announced the execution of transactions under its share buy-back program, initially launched on March 25, 2025, to repurchase up to 2.2 million shares. From May 5 to May 9, 2025, the company repurchased 179,797 shares, accumulating a total of 1,670,570 shares under the program. This initiative is part of Genmab’s strategy to reduce capital and fulfill commitments under its Restricted Stock Unit program, with the buy-back expected to conclude by July 10, 2025. These transactions reflect Genmab’s ongoing efforts to manage its capital structure effectively, potentially impacting its market positioning and shareholder value.
The most recent analyst rating on (GMAB) stock is a Hold with a $31.00 price target. To see the full list of analyst forecasts on Genmab stock, see the GMAB Stock Forecast page.
Spark’s Take on GMAB Stock
According to Spark, TipRanks’ AI Analyst, GMAB is a Outperform.
Genmab’s overall stock score reflects its strong financial performance and optimistic earnings call, highlighting revenue and profit growth and strategic investments. The valuation suggests potential undervaluation, while technical analysis indicates moderate strength. Key risks include dependency on major products and competitive pressures.
To see Spark’s full report on GMAB stock, click here.
More about Genmab
Genmab is an international biotechnology company headquartered in Copenhagen, Denmark, with a focus on developing innovative and differentiated antibody therapeutics. Established in 1999, the company has a strong presence across North America, Europe, and Asia Pacific. Genmab’s proprietary pipeline includes bispecific T-cell engagers, antibody-drug conjugates, next-generation immune checkpoint modulators, and effector function-enhanced antibodies, aiming to transform the lives of people with cancer and other serious diseases by 2030.
Average Trading Volume: 1,519,573
Technical Sentiment Signal: Sell
Current Market Cap: $12.2B
See more insights into GMAB stock on TipRanks’ Stock Analysis page.